Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing

Cancer Immunology Immunotherapy

Volumn 46, Issue 6, 1998, Pages 318-326

  Meropol, Neal J ^a   Barresi, Grace M ^a   Fehniger, Todd A ^a   Hitt, James ^a   Franklin, Margaret ^a   Caligiuri, Michael A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; LAK cells; Low dose IL 2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CHILL; CLINICAL ARTICLE; DIARRHEA; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; HEADACHE; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD56; BIOLOGICAL RESPONSE MODIFIERS; CELL DIVISION; CELL LINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOPHENOTYPING; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0031660981     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050493     Document Type: Article

References (24)

1. Bancroft GJ (1993) The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 4:503
2. Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman E, Stewart C, Hewitt RG, Fyfe G, Poiesz B, Caligiuri MA (1995) Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86:3287
3. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J (1990) Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171:1509
4. Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, Smith K, Ritz J (1991) Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: Prolonged immunomodulation without significant toxicity. J Clin Oncol 9:2110
5. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J Clin Invest 91:123
6. Manual of Oncologic Therapeutics (1991) Wittes RE (ed.) JB Lippincott, Philadelphia, pp 445-448
7. Caron PC, Lai LT, Scheinberg DA (1995) Inerleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1:63
8. Carson WE, Ross ME, Biocchi RA, Marien MJ, Boiani N, Grabstein K, Caligiuri MA (1995) Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 96:2578
9. Hayward JL, Carbone PP, Hensen JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89
10. Lindemann A, Brossart P, Hoffken K, Flabhove M, Voliotis D, Diehl V, Hecker G, Wagner H, Mertelsmann R (1993) Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase IB study. Cancer Immunol Immunother 37:307
11. Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA (1996) Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 2:669
12. Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76:2421
13. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J (1990) Human natural killer cell adhesion molecules. J Immunol 145:3194
14. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474
15. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195
16. Sleijfer DTh, Janssen RAJ, Buter J, Vries EGE de, Willemse PHB, Mulder NH (1992) Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119
17. Smith KA (1993) Lowest dose interleukin-2 immunotherapy Blood 81:1414
18. Soiffer RJ, Murray C, Gonin R, Ritz J (1994) Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964
19. Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J (1996) Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin-2. Clin Cancer Res 2:493
20. Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J (1997) Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. Clin Cancer Res 3:17
21. Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 80:60
22. Stewart CC, Stewart SJ (1995) Cell preparation for the identification of leukocytes. In: Darzynkiewicz Z, Robinson JP, Crissman HA (eds) Methods in cell biology series. Academic Press, New York, pp 40-59
23. Tripp CS, Wolf SF, Unanue ER (1993) Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and inlerleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 90:3725
24. Ziegler LD, Palazzolo P, Cunningham J, Janus M, Itoh K, Hayakawa K, Hellstrom I, Hellstrom KE, Nicaise C, Dennin R, Murray JL (1992) Phase I trial of murine monclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 10:1470